ac682
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT05080842)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Estrogen receptorDEGRADER
Estrogen receptor degrader
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05489679 | Phase 1 | Oct 1, 2022 | Accutar Biotechnology Inc |
| NCT05080842 | Phase 1 | Nov 30, 2021 | Accutar Biotechnology Inc, Tennessee Oncology, PLLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Accutar Biotechnology Inc | For profit | 2 | 2 | 1 | 2021 |
| Tennessee Oncology, PLLC | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1